Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Cutaneous T-cell lymphoma
ADR ID BADD_A09752
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.17      Lymphomas non-Hodgkin's T-cell
16.17.03      Mycoses fungoides
16.17.03.002      Cutaneous T-cell lymphoma
01      Blood and lymphatic system disorders
01.11      Lymphomas non-Hodgkin's T-cell
01.11.03      Mycoses fungoides
01.11.03.002      Cutaneous T-cell lymphoma
23      Skin and subcutaneous tissue disorders
23.07      Skin and subcutaneous tissue disorders NEC
23.07.04      Skin and subcutaneous conditions NEC
23.07.04.029      Cutaneous T-cell lymphoma
Description A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders. [MeSH]
MedDRA Code 10011677
MeSH ID D016410; D009182; D012751
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Cerebriform T lymphoma (Lukes-Collins Classification) | Cutaneous T-cell lymphoma | Mycosis fungoides | Mycosis fungoides (Working Formulation) | Mycosis fungoides NOS | Mycosis fungoides/Sezary syndrome | Mycosis fungoides/Sezary syndrome NOS | Sezary syndrome | Sezary's disease | Sezary's syndrome | Small cell cerebriform (Mycosis fungoides sezary syndrome) (Kiel Classification) | Lymphoma, T-Cell, Cutaneous | Lymphoma, T Cell, Cutaneous | T-Cell Lymphoma, Cutaneous | T Cell Lymphoma, Cutaneous | Cutaneous T-Cell Lymphoma | Cutaneous T Cell Lymphoma | Cutaneous T-Cell Lymphomas | Lymphoma, Cutaneous T-Cell | Lymphomas, Cutaneous T-Cell | T-Cell Lymphomas, Cutaneous | Granulomatous Slack Skin | Slack Skin, Granulomatous
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00036Acitretin0.001875%
BADD_D00156Apremilast0.000603%
BADD_D00269Bexarotene0.000168%
BADD_D00284Bortezomib--
BADD_D00551Cyclosporine0.000166%
BADD_D00680Dimethyl fumarate0.000400%
BADD_D00969Fosinoprilat0.010549%
BADD_D01083Hydrochlorothiazide0.000147%
BADD_D01119Ibrutinib0.000112%
BADD_D01136Imatinib0.000224%
BADD_D01265Levetiracetam0.000278%
BADD_D01359Mechlorethamine0.001735%
BADD_D01420Methoxsalen0.000781%
BADD_D01814Pralatrexate0.000168%
BADD_D01834Prednisone0.000009%
BADD_D01933Ribavirin0.009890%
BADD_D01964Romidepsin--
BADD_D01978Ruxolitinib0.000137%
BADD_D02105Tacrolimus0.000743%
BADD_D02331Valsartan0.000053%
BADD_D02344Vemurafenib0.000168%
BADD_D02370Vorinostat0.000112%
BADD_D02375Water--
BADD_D02407Upadacitinib--
BADD_D02464Fingolimod0.001447%
The 1th Page    1    Total 1 Pages